Literature DB >> 6699465

Comparative effects of germfree and ambient environments on the development of cystic kidney disease in CFWwd mice.

A A Werder, M A Amos, A H Nielsen, G H Wolfe.   

Abstract

A spontaneously occurring murine renal cystic disease that resembles human adult-onset polycystic renal disease is described. The disease that develops in CFWwd mice is characterized by multiple bilateral cysts in the kidneys in all affected animals and hepatic cysts in approximately 20% of these animals with disease. Occasional thoracic aortic aneurysms were also observed in animals with cystic disease. The prevalence of the disease appears to be determined by the degree of exposure to the ambient environment. A germfree colony of CFWwd mice only rarely displayed the disease, whereas virtually 100% of animals housed for their entire life in the ambient environment died with the disease. Germfree mice removed from the axenic environment and placed in the ambient environment developed the disease, but at a lower prevalence than those animals born and reared in the ambient environment. Disease prevalence in animals reared in environmentally protected caging was between that in germfree and conventional animals. Genetic studies of AKR mice indicated that the disease is inherited in an autosomal dominant fashion but with reduced penetrance.

Entities:  

Mesh:

Year:  1984        PMID: 6699465

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

Review 1.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 2.  Metabolic Abnormalities in Diabetes and Kidney Disease: Role of Uremic Toxins.

Authors:  Laetitia Koppe; Denis Fouque; Christophe O Soulage
Journal:  Curr Diab Rep       Date:  2018-09-08       Impact factor: 4.810

Review 3.  Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Vicente E Torres
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

Review 4.  Gut microbial metabolites as multi-kingdom intermediates.

Authors:  Kimberly A Krautkramer; Jing Fan; Fredrik Bäckhed
Journal:  Nat Rev Microbiol       Date:  2020-09-23       Impact factor: 60.633

Review 5.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

6.  Polycystic kidney rat is a novel animal model of Caroli's disease associated with congenital hepatic fibrosis.

Authors:  T Sanzen; K Harada; M Yasoshima; Y Kawamura; M Ishibashi; Y Nakanuma
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

7.  Hereditary polycystic kidney disease. Adult polycystic kidney disease associated with renal hypertension, renal osteodystrophy, and uremic enteritis in SPRD rats.

Authors:  J Kaspareit-Rittinghausen; F Deerberg; A Wcislo
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

Review 8.  The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease.

Authors:  Tao Yang; Elaine M Richards; Carl J Pepine; Mohan K Raizada
Journal:  Nat Rev Nephrol       Date:  2018-07       Impact factor: 28.314

Review 9.  Polycystic kidney disease: an unrecognized emerging infectious disease?

Authors:  M A Miller-Hjelle; J T Hjelle; M Jones; W R Mayberry; M A Dombrink-Kurtzman; S W Peterson; D M Nowak; F S Darras
Journal:  Emerg Infect Dis       Date:  1997 Apr-Jun       Impact factor: 6.883

10.  Loss of Fnip1 alters kidney developmental transcriptional program and synergizes with TSC1 loss to promote mTORC1 activation and renal cyst formation.

Authors:  Ryan Centini; Mark Tsang; Terri Iwata; Heon Park; Jeffrey Delrow; Daciana Margineantu; Brandon M Iritani; Haiwei Gu; H Denny Liggitt; Janella Kang; Lim Kang; David M Hockenbery; Daniel Raftery; Brian M Iritani
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.